OptimizeRx reported quarterly EPS of $0.14, beating the Zacks Consensus Estimate of $0.01 by $0.13 per share and improving from $0.08 a year ago. The result indicates a solid earnings beat and year-over-year growth, which is modestly supportive for the stock.
OptimizeRx reported quarterly EPS of $0.14, beating the Zacks Consensus Estimate of $0.01 by $0.13 per share and improving from $0.08 a year ago. The result indicates a solid earnings beat and year-over-year growth, which is modestly supportive for the stock.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
mildly positive
Sentiment Score
0.34
Ticker Sentiment
